MK-677 vs Ipamorelin: Oral vs Injectable GH Secretagogue Comparison
MK-677 (Ibutamoren) is an oral non-peptide ghrelin mimetic that provides sustained 24-hour growth hormone and IGF-1 elevation without injections. Ipamorelin is an injectable selective GHRP that produces clean, pulsatile GH release with minimal cortisol, prolactin, or appetite side effects. This comparison covers the key trade-offs between oral convenience and injectable precision for growth hormone research.
Side-by-Side Comparison
Class
Non-peptide ghrelin mimetic (GHS)
GHRP (Growth Hormone Releasing Peptide)
Mechanism
Sustained ghrelin/GHS receptor agonism
Selective ghrelin/GHS receptor agonism (pulsatile)
Evidence Grade
B+
Route
Oral (capsule/liquid)
Subcutaneous injection
Typical Dose
10 - 25 mg once daily
200 - 300 mcg, 2-3x daily
Half-Life
~24 hours
~2 hours
GH Release Pattern
Sustained elevation (24h)
Pulsatile (mimics natural rhythm)
IGF-1 Elevation
Significant, sustained increase
Moderate, pulsatile increase
Appetite Impact
Significant increase (common)
Minimal
Blood Sugar Impact
May increase fasting glucose
Cortisol Impact
Possible mild increase
Minimal (selective)
Water Retention
Common (moderate to significant)
Mild
Sleep Quality
Often improves (deep sleep)
May improve when dosed before bed
Convenience
High (once-daily oral)
Low (2-3 daily injections)
FDA Status
Not approved; investigational
Not approved; research compound
Cost (research grade)
$
MK-677: Pros & Cons
Advantages
Oral dosing eliminates injection requirement
Once-daily dosing with 24-hour half-life
Sustained GH and IGF-1 elevation around the clock
Significant improvement in sleep quality
Well-studied with multiple human clinical trials
Low cost and widely available
Considerations
Significant appetite increase (problematic for some)
May raise fasting blood glucose and insulin resistance
Notable water retention and bloating
Non-pulsatile GH release (less physiological)
Possible cortisol elevation in some individuals
Long-term safety data limited beyond 2 years
Ipamorelin: Pros & Cons
Cleanest side effect profile among GH secretagogues
Pulsatile GH release mimics natural physiology
No significant cortisol or prolactin elevation
Minimal appetite stimulation
No impact on blood glucose or insulin sensitivity
Excellent synergy when combined with GHRH analogs
Requires 2-3 subcutaneous injections daily
Short half-life (~2 hours) limits duration of effect
Lower total 24-hour GH elevation than MK-677
Requires reconstitution and proper storage
Best results need GHRH analog combination
Injection compliance can be challenging
Which Is Right for Your Research?
Decision Guide
Choose MK-677 if: Oral convenience is a priority, you want sustained 24-hour GH/IGF-1 elevation, or you are researching sleep quality and appetite effects. MK-677 is ideal for long-term GH optimization studies where injection compliance is a barrier. Be prepared for appetite increase and monitor blood glucose.
Choose Ipamorelin if: You want the cleanest, most selective GH release without metabolic side effects. Ipamorelin is ideal for researchers who prioritize pulsatile, physiological GH patterns and want to avoid appetite stimulation, blood sugar changes, and water retention. Best results come from combining with CJC-1295 or sermorelin.
Key trade-off: MK-677 wins on convenience and sustained IGF-1 elevation. Ipamorelin wins on selectivity, safety profile, and physiological GH patterning. The choice ultimately depends on whether convenience or precision matters more for your research objectives.
Frequently Asked Questions
It depends on priorities. MK-677 offers oral convenience with sustained 24-hour GH/IGF-1 elevation. However, it increases appetite, may elevate blood sugar, and causes water retention. Ipamorelin produces cleaner, selective GH pulses without these side effects but requires multiple daily injections. For clean GH release, ipamorelin is superior. For convenience, MK-677 wins.
Some researchers combine them, though this is less common than ipamorelin + CJC-1295. Since both act through the ghrelin/GHS receptor pathway, combining them may not produce the same synergy as a GHRP + GHRH combination. If combined, lower doses of each are typically used.
Yes. MK-677's sustained ghrelin receptor activation can increase fasting blood glucose by 5-10 mg/dL on average. Ipamorelin's brief, pulsatile GH release does not significantly impact blood sugar or insulin sensitivity, making it the better choice for metabolic-sensitive research.
Related Protocol Guides
Verified Research Suppliers
Research-grade peptides are available from verified suppliers listed on our Vendor Comparison page. All listed vendors meet cGMP certification and third-party testing standards.
Related Tools & Resources
Related Resources